Microsoft word - final list marked up - 01.07.03.doc
SCHEDULE 1 PROHIBITED SUBSTANCES
Where a Prohibited Substance (as listed below) is capable of being produced by the body
naturally, a sample will be deemed to be positive where the concentration of the Prohibited
Substance or its metabolites or markers and/or any other relevant ratio(s) in the athlete’s
body tissues or fluids so exceeds, or deviates from, the range of values normally found in
humans so as not to be consistent with normal endogenous production.
A sample may not be regarded as positive for a Prohibited Substance in any such case where
the athlete proves by clear and convincing evidence that the concentration of the Prohibited
Substance or its metabolites or markers and/or the relevant ratio(s) in the athlete’s body
tissues or fluids is attributable to a pathological or physiological condition.
Evidence from metabolic profiles and/or the measurement of isotopic ratios (isotope ratio
mass spectrometry) may be used to draw definitive conclusions as to the exogenous origin of
a Prohibited Substance or its metabolites.
(a) Anabolic
dehydrochlormethyltestosterone norbolethone
and chemically or pharmacologically related compounds and precursors.
* In the case of a suspicious finding for testosterone, it is mandatory that a further
investigation be conducted in accordance with the IAAF T/E Protocol before the
*The definition of a positive finding for salbutamol as an anabolic agent is one in
which the concentration of non-sulphated salbutamol in urine exceeds 1000
nanograms per millilitre. If the concentration of non-sulphated salbutamol in urine is
less than 1000 nanograms per millilitre, it will be treated as a positive finding for a
and chemically or pharmacologically related compounds.
Peptide Hormones, Mimetics and Analogues
Chorionic Gonadotrophin (hCG - human chorionic gonadotrophin – prohibited in
males only): it is known that the administration to males of human chorionic
gonadotrophin and other compounds with related activity can lead to an increased
rate of production of endogenous androgenic steroids and is considered equivalent to
the exogenous administration of testosterone.
Pituitary and Synthetic Gonadotrophins (LH – prohibited in males only)
Corticotrophins (ACTH, Tetracosactide): corticotrophin has been misused to
increase the blood levels of endogenous corticosteroids notably to obtain the
euphoric effect of corticosteroids. The application of corticotrophin is considered to
be equivalent to the oral, intra-muscular or intravenous application of
glucocorticosteroids (see PART I (e) below).
Hormone (hGH, somatotrophin): the misuse of growth hormone in sport is
deemed to be unethical and dangerous because of various adverse effects, for
example, allergic reactions, diabetogenic effects, and acromegaly when applied in
Recombinant Erythropoietin (r-EPO) – a sample will be deemed to be positive for r-EPO where a laboratory detects its presence in a urine sample provided by an athlete. Blood samples may be used as an aid to the detection of r-EPO, or as providing (where relevant and appropriate) corroborative evidence of its presence in a urine sample. Darbepoietin, NESP, Dynepo and any other substance which is an analogue or mimetic of these substances (or of r-EPO) is also prohibited. In such cases, the circumstances in which a sample is to be deemed to be positive, and the evidence necessary to establish this, shall be those described in the definition of r-EPO above.
Insulin: permitted only to treat insulin-dependent diabetes, with written notification
by an endocrinologist (for IAAF exemption procedure, see Chapter 5 above).
All the respective releasing factors (and their mimetics and analogues) of the above-
The systemic use of glucocorticosteroids is prohibited when administered orally,
rectally, or by intravenous or intramuscular injection. Where medically necessary,
local and intra-articular injections of glucocorticosteroids are permitted.
Aromatase inhibitors, clomifene, cyclofenil, tamoxifen - prohibited in males only.
and chemically or pharmacologically related compounds
* For caffeine, the definition of a positive finding is one in which the
concentration in urine exceeds 12 micrograms per millilitre. A sample may not
be regarded as positive for caffeine where an athlete proves by clear and
convincing evidence that the elevated concentration is attributable to the athlete
having an impaired caffeine metabolism condition.
For cathine, the definition of a positive finding is one in which the
concentration in urine exceeds 5 micrograms per millilitre. For ephedrine and
methylephedrine, the definition of a positive finding is one in which the
concentration in urine exceeds 10 micrograms per millilitre. For
phenylpropanolamine and pseudoephedrine, the definition of a positive finding
is one in which the concentration in urine exceeds 25 micrograms per millilitre.
Exceptionally, the administration of the Beta-2-agonists formoterol, salbutamol,
salmeterol or terbutaline are permitted by inhalation where prescribed for therapeutic
purposes by properly qualified medical personnel and where prior clearance has been
given by the relevant National Federation or the IAAF in accordance with the IAAF
and chemically or pharmacologically related compounds
For morphine, the definition of a positive finding is one in which the concentration
of free and conjugated morphine in the urine exceeds 1 microgram per millilitre
unless there is a simultaneous finding of codeine or other permitted substance
which may explain the finding of morphine.
Substances and prohibited techniques to be detected during
Peptide Hormones, Mimetics and Analogues
The expression "prohibited techniques" shall include the following:
Blood doping including any sort of blood transfusion or administration
of red blood cell products of any origin, other than for legitimate
The administration of r-EPO or other erythropoiesis-stimulating
proteins (e.g. Darbepoietin, NESP, Dynepo and others) or products that
enhance the uptake, transport or delivery of oxygen, e.g. modified
haemoglobin products including, but not limited to, bovine and cross-
linked haemoglobins, microencapsulated haemoglobin products,
Masking agents and pharmacological, chemical and physical manipulation
The use or attempted use of substances and/or techniques which may alter, the
integrity and validity of samples used in doping controls are prohibited.
Examples of masking agents: diuretics (e.g. furosemide, hydrochlorothiazide),
epitestosterone*, probenecid, plasma expanders (e.g. hydroxyethylstarch).
*The definition of a positive finding for epitestosterone is one in which the concentration of epitestosterone exceeds 200 ng/ml.
Examples of prohibited techniques are catheterisation, urine substitution and/or
tampering, inhibition of renal excretion.
Gene or cell doping is defined as the non-therapeutic use of genes, genetic elements and/or cells that have the capacity to enhance athletic performance.
Financial Times FT.Com ( PharmaWire) Pharmawire is part of The Mergermarket Group which is a division of the Financial Times Group, publisher of the Financial Times newspaper, FT.com, Expansion and FT Deutchsland. The FT Group is a division of Pearson plc, the international media group. Roche: Boniva patent prosecution history and repeated challenges on biphosphonate class expected to